

A

TUMOR SPECIFIC ASSAY FOR CA125 OVARIAN CANCER ANTIGENFIELD OF THE INVENTION

5 The present invention relates to a novel subunit of an ovarian tumor-associated antigen useful in detection of ovarian cancer. It also relates to a method of diagnosis and monitoring of ovarian tumors utilizing the novel subunit as an indicator.

GOVERNMENT SUPPORT

10 The present invention was supported in part by the National Institute of Health, Grant No. 40406.

BACKGROUND OF THE INVENTION

15 The effective detection and diagnosis of cancer at an early stage in its development may be critical in the ultimate successful treatment of the disease. It is further extremely important that the diagnosis accurately pinpoint the type or location of the tumor since different tumor types may frequently require the use of different chemotherapeutic or treatment regimens. Finally, it is also necessary that the testing procedure used in diagnosis be precise to such an extent that there is minimal danger that either false positives or false negatives will produce an inaccurate diagnosis.

25 In this connection, the various procedures coming under the heading of "immunoassay" have shown particular promise in development of tumor specific diagnostic testing. Immunoassay relies, in principle, on the natural reactions of the body's immune system to the presence of foreign substances introduced into the body. The immune system is provoked by these foreign materials, for example, infectious organisms such as bacteria or viruses, to produce antibodies which react specifically with the foreign substance (or

L

1 antigen) and which, if effective, aid in the elimination of  
the organisms or foreign matter from the body. The  
production of antibodies, of course, is not limited to the  
presence of infectious microorganisms but is also observed in  
5 response to many materials which are not normally found in  
circulation in the body such as cancerous cells, foreign  
blood group antigens, or fetus-specific antigen.

The relative specificity of antibody for a  
particular antigen has provided the basis for highly specific  
and accurate diagnostic testing for various physiological  
10 conditions such as infectious diseases, specific tumors,  
pregnancy and presence of drugs in the body. In practice,  
the test operates by exposing a test sample suspected of  
containing a specific antigen associated with a particular  
disease condition, or antibodies to a particular micro-  
15 organism, such as the AIDS virus, to a detectably labelled  
corresponding "immunological partner," i.e., the correspond-  
ing antibody or antigen. Alternately, in a "sandwich" type of  
assay, a test sample containing the antigen to be detected is  
added to a corresponding antibody, and this is followed by  
20 addition of a second labelled antibody to the antigen,  
providing a detectably labelled "sandwich," indicating the  
antigen's presence. Competitive binding assays also exist,  
in which the relative amount of binding of an antigen mimic  
to an antigen-specific antibody in the test sample is used to  
25 indicate the relative amount of antigen present in the  
sample. In all these immunoassays, a reaction between  
antigen and antibody indicates the presence of the suspected  
condition, the reaction being made visibly detectable by the  
presence of a label on the antigen or antibody. The most  
30 frequently used labels are enzymes, to which a substrate is  
added, causing a catalytic reaction producing a color change;

3

1 also commonly used are fluorescent, chemiluminescent or  
radioactive molecules. A wide range of variations on immuno-  
assay techniques are currently available as can be seen, for  
example, by reference to U.S. Patent Nos. 4,016,043; -  
4,424,279 and 4,018,653. <sup>B</sup>

5 <sup>B</sup> The successful development of an accurate  
immunoassay for disease detection, of course, requires that  
an appropriate antigen or antibody is available with which to  
conduct the assay. For example, the ideal antigen is one  
10 which is highly specific to the particular condition of  
interest, the identification of which, in the test sample,  
will definitively show the presence of the causative agent or  
other associated factor. Such antigens would include, for  
example, a lipopolysaccharide peculiar to a particular  
15 species of bacterium; a glycoprotein only found in the coat  
of a specific type of virus; or cell surface antigens only  
found in abnormal cell types such as tumor cells. The  
selection of the appropriate antigen is critical to the  
accuracy of any diagnosis since selection of an antigen which  
20 is not specific to a particular cell type or species may  
result in a large number of false positive reactions by  
identification of unrelated cells or organisms also carrying  
the antigen.

A particular effort has been made to identify tumor  
cell antigens as markers for specific types of tumors.  
25 Developments of a test which can identify a disease connected  
antigen with specificity will be of substantial value to the  
clinician not only in early diagnosis, but also in evaluating  
the progression of the disease and determining effectiveness  
of ongoing therapy. Some success has been achieved in the  
30 development of immunoassays for tumor specific antigens. For  
example, human chorionogonadotropin (hCG) has been

4

1 effectively applied to the monitoring of trophoblastic  
disease. Similarly, certain other antigens, such as  
alphafetoprotein (AFP), prostatic acid phosphatase (PAP) and  
carcinoembryonic antigen (CEA), have all been effectively  
5 been employed in detection and monitoring of tumors in  
general and in particular connection with testicular,  
prostate and colorectal carcinomas. However, outside the  
aforementioned collection of substances, there has been a  
relative dearth of other antigens which are truly useful in  
10 accurate diagnosis and monitoring; this has been proven  
particularly true with respect to gynecologic malignancies,  
especially ovarian carcinomas, which have frequently already  
spread throughout the pelvic cavity before diagnosis of the  
condition. Many of these carcinomas typically exhibit a very  
15 aggressive growth pattern and generally respond well to  
chemotherapy. Thus, an accurate method by which early  
diagnosis could be obtained in these diseases is highly  
desirable.

A substantial amount of research has been devoted  
to isolating antigens which may be useful in the selective  
20 detection of ovarian carcinomas. For example, <sup>Knauf</sup>~~Knaaf~~ and  
<sup>B</sup>~~L~~ Urback (Am. J. Obstet. Gynecol. 138: 1222, 1980; Cancer Res.  
41: 1351, 1981) have described an antigen named OCA which is  
<sup>B</sup> significantly elevated in the plasma of 76% of <sup>patients</sup>~~patients~~ with  
25 ovarian cancer; unfortunately, the antigen also occurs at  
<sup>B</sup> high levels in about 10% of <sup>patients</sup>~~patients~~ with benign gynecologic  
disorders, pregnant females and disease free controls, thus  
potentially rendering a positive test result unreliable.  
<sup>B</sup> Similarly, Smith and Ol (Obstet. & Gynecol. Surv. 39: 346,  
1984) report an ovarian cancer associated antigen, but this  
30 antigen has not yet been evaluated as to its specificity and  
suitability in diagnosis or monitoring of afflicted patients.

1 A recent discovery by Bast, et al. (N. Engl. J.  
2 Med. 309: 883 (1983) of a serous cystadinocarcinoma ovarian  
3 antigen, known as CA125, has proven to be of significant  
4 value in monitoring patients with ovarian cancer. This  
5 antigen was isolated by using a monoclonal antibody, OC125,  
6 raised by stimulation of mice with ovarian cancer cell line  
7 OVCA 433. It has been shown to recognize cell surface  
8 antigens of the OVCA 433 cell as well as 13 of 14 other  
9 ovarian cancer cell lines and a melanoma cell line. The  
10 antigen is a high molecular weight (>200,000 daltons) glyco-  
11 protein which has been partially purified from tissue culture  
12 medium (Masuko, et al., Cancer Res. 44: 2813, 1984). With  
13 use of the aforementioned monoclonal antibody, sera of  
14 several patients with various types of cancer was tested for  
15 the presence of CA125. Results showed that 83% of patients  
16 with ovarian cancer had elevated levels (>35 units/ml),  
17 whereas only 1% of 888 normal patients <sup>22</sup>sera showed titers  
18 above this level. Although data indicate a certain level of  
19 non-ovarian specificity of the CA125 antigen, the observation  
20 of rising and falling levels of antigen with progression and  
21 regression of the disease in patients with ovarian cancer  
22 show utility of the antigen in monitoring the progress of the  
23 disease in already diagnosed patients. The use of CA125 for  
24 diagnostic purposes is further complicated by the fact it  
25 appears to be, to some extent, a normal product of  
26 development. Significant quantities have been found in  
27 amniotic fluid during gestation (O'Brien, et al., Soc. Gyn  
28 Invest. Abstract, p.54, March, 1985. It has also been found  
29 to increase in connection with benign disease conditions such  
30 as endometriosis or pelvic inflammatory diseases. The  
31 existence of even small amounts of CA125 in normal tissue  
32 provides a significant chance of cross reactivity of the

CA125-specific antibodies with non-tumor tissues as well as with cancerous tissues. Therefore, again, although there is substantial promise in the CA125 antigen as a potential marker for ovarian cancer, there has not yet been determined a method by which interference from non-ovarian tumor and normal tissue levels of CA125 can be eliminated. Further, the known monoclonal antibody OC125 appears to react with both the normal and tumor antigen. Therefore, there still does not exist a truly ovarian tumor specific immunoassay which can reliably be used to detect and monitor the ovarian carcinomas without the possibility of cross-reaction with normal tissue. It has now been unexpectedly discovered that the antigen CA125 contains a heretofore undiscovered subunit which appears to be specific to ovarian tumor-associated CA125. Normal tissue tested has failed to show the presence of this fraction of the CA125 molecule. Thus, the discovery of this unique subunit now presents a means by which the testing procedure utilizing CA125 as a marker for ovarian cancer can be refined to reduce or eliminate cross reaction with non-ovarian tumor associated CA125 antigen.

BRIEF DESCRIPTION OF THE INVENTION

The present invention relates to a subunit of CA125 antigen having a molecular weight of about 40,000 daltons, said subunit being found only in tumor associated CA125 antigen.

The invention also relates to a monoclonal antibody having specificity for the 40,000 daltons subunit of tumor-associated CA125.

The invention further relates to a method of detection or monitoring of ovarian cancer which comprises contacting serum of an individual suspected of having ovarian cancer with an antibody having specificity for the 40,000 dalton subunit of tumor-associated CA125.

DE CL 1  
DETAILED DESCRIPTION OF THE INVENTION

1 The discovery of a unique tumor-associated CA125  
subunit has now provided a means by which sera of  
tumor-afflicted patients may be readily distinguished from  
5 sera of normal patients or those with benign gynecologic  
disorders. The novel subunit, which is readily isolatable  
from CA125 antigen, can then be used to prepare monoclonal  
antibodies which, when used in an immunoassay, will be  
capable of differentiating normal from tumor-associated sera  
10 by its specificity for the tumor-associated subunit.

15 CA125, the source of the relevant subunit, may be  
isolated from serum of patients known to have ovarian tumors.  
Although the antigen may be isolated by any of the methods  
known in the art for glycoprotein isolation, the most  
reliable method by which this may be achieved is by isolation  
using the CA125 antibody (available as a kit from Centocor  
Corp.), whereby the CA125 antigen is isolated by exposure  
to the bead bound monoclonal antibody. Alternately, the  
CA125 antigen may be purified by molecular filtration. The  
20 40KD subunit may then be isolated by electrophoresis of the  
CA125 antigen, followed by excision and elution of the 40KD  
band.

25 The subunit thus purified is then utilized in  
antibody production. Both polyclonal and monoclonal  
antibodies are obtainable by immunization with the present  
subunit, and either type is utilizable for the present  
immunoassays. The methods of obtaining both types of sera  
are well known in the art. Polyclonal sera are less  
30 preferred but are relatively easily prepared by injection of  
a suitable laboratory animal with an effective amount of the  
purified antigenic subunit, collecting serum from the animal,  
and isolating subunit-specific sera by any of the known  
immunoabsorbent techniques. Although antibodies produced by

1 this method are utilizable in virtually any type of  
immunoassay, they are generally less favored because of the  
potential heterogeneity of the product.

5 The use of monoclonal antibodies in the present  
immunoassay is particularly preferred because of the ability  
to produce them in large quantities and the homogeneity of  
the product. The preparation of hybridoma cell lines for  
monoclonal antibody production derived by fusing an immortal  
10 cell line and lymphocytes sensitized against the immunogenic  
preparation can be done by techniques which are well known to  
those who are skilled in the art. (See, for example,  
Douillard, J. Y. and Hoffman, T., "Basic Facts About  
Hybridomas," in "Compendium of Immunology Vol. II, L.  
Schwartz (Ed.) (1981); Kohler, G. and Milstein, C., Nature  
15 256, 495-497 (1975); European Journal of Immunology, Vol. 6,  
pp. 511-519 (1976), Koprowski, et al., U.S. Patent 4,172,124,  
Koprowski, et al., U.S. Patent 4,196,265 and Wands, U.S.  
Patent 4,271,145, the teachings of which are herein  
incorporated by reference.)

20 Unlike preparation of polyclonal sera, the choice  
of animal is dependent on the availability of appropriate  
immortal lines capable of fusing with lymphocytes thereof.  
Mouse and rat have been the animals of choice in hybridoma  
technology and are preferably used. Humans can also be  
25 utilized as sources for sensitized lymphocytes if appropriate  
immortalized human (or nonhuman) cell lines are available.  
For the purpose of the present invention, the animal of  
choice may be injected with about 10<sup>8</sup>ug of the purified  
subunit. Usually the injecting material is emulsified in  
30 Freund's complete adjuvant. Boosting injections may also be  
required. The detection of antibody production can be  
carried out by testing the antisera with appropriately  
labeled antigen. Lymphocytes can be obtained by removing the  
spleen or lymph nodes of sensitized animals in a sterile



1 fashion and carrying out fusion. Alternately, lymphocytes  
can be stimulated or immunized in vitro, as described, for  
example, in C. Reading J. Immunol. Meth. 53: 261-291, 1982.

A number of cell lines suitable for fusion have  
5 been developed, and the choice of any particular line for  
hybridization protocols is directed by any one of a number of  
criteria such as speed, uniformity of growth characteristics,  
deficiency of its metabolism for a component of the growth  
medium, and potential for good fusion frequency.

10 Intraspecies hybrids, particularly between like  
strains, work better than interspecies fusions. Several cell  
lines are available, including mutants selected for the loss  
of ability to secrete myeloma immunoglobulin. Included among  
these are the following mouse myeloma lines: MPC<sub>11</sub>-X45-6TG,  
15 B P3-NS1-1-Ag4-1, P3-X63-Ag8, or mutants thereof such as  
B X63-Ag8.653, SP2-0-Ag14 (all BALB/C derived), Y3-'Ag1.2.3  
B (rat), and U266 (human).

Cell fusion can be induced either by virus, such as  
Epstein-Barr or Sendai virus, or polyethylene glycol.  
20 Polyethylene glycol (PEG) is the most efficacious agent for  
the fusion of mammalian somatic cells. PEG itself may be  
toxic for cells, and various concentrations should be tested  
for effects on viability before attempting fusion. The  
molecular weight range of PEG may be varied from 1,000 to  
25 6,000. It gives best results when diluted to about 50% w/w  
in saline or serum-free medium. Exposure to PEG at 37°C for  
about 30 seconds is preferred in the present case, utilizing  
murine cells. Extremes of temperature should be avoided, and  
preincubation of each component of the fusion system at 37°C  
30 prior to fusion gives optimum results. The ratio between  
lymphocytes and malignant cells should be optimized to avoid  
cell fusion among spleen cells. Myeloma-lymphocyte ratios  
ranging from 1:1 to 1:10 give good results.

1           The successfully fused cells can be separated from  
the myeloma line by any technique available to the art. The  
most common and preferred method is to choose a malignant  
line which is Hypoxanthine Guanine Phosphoribosyl Transferase  
(HGPRT) deficient, which will not grow in an aminopterin-  
5 containing medium used to allow only growth of hybrids is  
B generally composed of hypoxanthine  $1 \times 10^{-4}$ , aminopterin  
B  $1 \times 10^{-5}$  M, and thymidine  $3 \times 10^{-5}$  M, commonly known as the HAT  
medium. The fusion mixture can be grown in the HAT-  
10 containing culture medium immediately after the fusion or 24  
hours later. The feeding schedules usually entail B  
maintenance in HAT medium for two weeks and then feeding  
with either regular culture medium or hypoxanthine,  
thymidine-containing medium.

15           The growing colonies are then tested for the  
presence of antibodies that recognize the antigenic  
preparation. Detection of hybridoma antibodies can be  
performed using an assay where the antigen is bound to a  
solid support and allowed to react to hybridoma supernatants  
20 containing putative antibodies. The presence of antibodies  
may be detected by "sandwich" techniques using a variety of  
indicators. Most of the common methods are sufficiently  
sensitive for use in the range of antibody concentrations  
secreted during hybrid growth.

25           Cloning of hybrids can be carried out after 21-23  
days of cell growth in selected medium. Cloning can be B 14 B  
performed by cell limiting dilution in fluid phase or by  
directly selecting single cells growing in semi-solid  
agarose. For limiting dilution, cell suspensions are diluted  
30 serially to yield a statistical probability of having only  
one cell per well. For the agarose technique, hybrids are

//

1 seeded in a semisolid upper layer, over a lower layer  
containing feeder cells. The colonies from the upper layer  
may be picked up and eventually transferred to wells.

5 Antibody-secreting hybrids can be grown in various  
tissue culture flasks, yielding supernatants with variable  
concentrations of antibodies. In order to obtain higher  
concentrations, hybrids may be transferred into animals to  
obtain inflammatory ascites. Antibody-containing ascites can  
be harvested 8-12 days after intraperitoneal injection. The  
ascites contain a higher concentration of antibodies but  
10 include both monoclonals and immunoglobulins from the  
inflammatory ascites. Antibody purification may then be  
achieved by, for example, affinity chromatography.

15 The presence of the CA125 40KD subunit antigen in a  
patient's serum can be detected utilizing these antibodies,  
either monoclonal or polyclonal, in virtually any type of  
immunoassay. This, of course, includes both single-site and  
two-site, or "sandwich," assays of the non-competitive types,  
as well as in traditional competitive binding assays.

20 Sandwich assays are among the most useful and commonly used  
assays and are favored for use in the present invention. A  
number of variations of the sandwich assay technique exist,  
and all are intended to be encompassed by the present  
invention. Briefly, in a typical forward assay, an unlabeled  
25 antibody is immobilized on a solid substrate and the sample  
to be tested brought into contact with the bound molecule.  
After a suitable period of incubation, for a period of time  
sufficient to allow formation of an antibody-antigen binary  
complex, a second antibody, labeled with a reporter molecule  
30 capable of producing a detectable signal is then added and  
incubated, allowing time sufficient for the formation of a  
ternary complex of antibody-labeled antibody. Any unreacted

12

1 material is washed away, and the presence of the antigen is  
determined by observation of a signal produced by the  
reporter molecule. The results may either be qualitative, by  
simple observation of the visible signal, or may be  
5 quantitated by comparing with a control sample containing  
known amounts of hapten. Variations on the forward assay  
include a simultaneous assay, in which both sample and  
labeled antibody are added simultaneously to the bound  
antibody, or a reverse assay in which the labeled antibody  
10 and sample to be tested are first combined, incubated and  
then added to the unlabeled surface bound antibody. These  
techniques are well known to those skilled in the art, and  
then possibly of minor variations will be readily apparent.  
As used herein, "sandwich assay" is intended to encompass all  
variations on the basic two-site technique.

15 The antigen may also be detected by a competitive  
binding assay in which a limiting amount of antibody specific  
for the molecule of interest (either an antigen or hapten) is  
combined with specified volumes of solutions containing an  
unknown amount of the molecule to be detected and a solution  
20 containing a detectably labeled known amount of the molecule  
to be detected or an analogue thereof. Labeled and unlabeled  
molecules then compete for the available binding sites on the  
antibody. Phase separation of the free and antibody-bound  
molecules allows measurement of the amount of label present  
25 in each phase, thus indicating the amount of antigen or  
hapten in the sample being tested. A number of variations in  
these general competitive binding assays currently exist.

30 In any of the known immunoassays, for practical  
purposes, one of the antibodies will be typically bound to a  
solid phase and a second molecule, either the second antibody  
in a sandwich assay, or, in a competitive assay, the known

13

1 amount of antigen, will bear a detectable label or reporter  
molecule in order to allow visual detection of an antibody<sup>2</sup>  
antigen reaction. When two antibodies are employed, as in  
the sandwich assay, it is only necessary that one of the  
antibodies be specific for the 40KD subunit, while the other  
5 B may be specific for the subunit<sup>6</sup> or for the CA125 antigen.  
The following description will relate to a discussion of a  
typical forward sandwich assay; however, the general  
techniques are to be understood as being applicable to any of  
the contemplated immunoassays.

10 In the typical forward sandwich assay, a first  
antibody having specificity for the subunit molecule is  
either covalently or passively bound to a solid surface. The  
solid surface is typically glass or a polymer, the most  
commonly used polymers being cellulose, polyacrylamide,  
15 nylon, polystyrene, polyvinyl chloride or polypropylene. The  
solid supports may be in the form of tubes, beads, discs or  
microplates, or any other surface suitable for conducting an  
immunoassay. The binding processes are well-known in the  
art and generally consist of cross-linking covalently binding  
20 or physically adsorbing the molecule to the insoluble  
carrier. Following binding, the polymer-antibody complex is  
washed in preparation for the test sample. An aliquot of the  
sample to be tested is then added to the solid phase complex  
and incubated at 25°C for a period of time sufficient to  
25 allow binding of any subunit present to the antibody. The  
incubation period will vary but will generally be in the  
range of about 2-40 minutes. Following the incubation  
period, the antibody subunit solid phase is washed and dried  
and incubated with a second antibody specific for a portion  
30 of the hapten. The second antibody is linked to a reporter  
molecular which is used to indicate the binding of the second  
antibody to the hapten. By "reporter molecule," as used in  
the present specification and claims, is meant a molecule

1 which, by its chemical nature, provides an analytically  
indicatable signal which allows the detection of antigen-  
bound antibody. Detection may be either qualitative or  
quantitative. The most commonly used reporter molecules in  
5 this type of assay are either enzymes, fluorophores or  
radionuclide containing molecules. In the case of an enzyme  
immunoassay, an enzyme is conjugated to the second antibody,  
generally by means of glutaraldehyde or periodate. As will  
be readily recognized, however, a wide variety of different  
10 conjugation techniques exist, which are readily available to  
the skilled artisan. Commonly used enzymes include  
horseradish peroxidase, glucose oxidase,  $\beta$ -galactosidase and  
alkaline phosphatase, among others. The substrates to be  
used with the specific enzymes are generally chosen for the  
15 production, upon hydrolysis by the corresponding enzyme, of a  
detectable color change. For example, p-nitrophenyl  
phosphate is suitable for use with alkaline phosphatase  
conjugates; for peroxidase conjugates, 1,2-phenylenediamine,  
5-aminosalicylic acid, or toluidine are  $\beta$  commonly used. It is  
20 also possible to employ fluorogenic substrates, which yield a  
fluorescent product rather than the chromogenic substrates  
noted above. In all cases, the enzyme-labeled antibody is  
added to the first antibody hapten complex, allowed to bind,  
and then to the first antibody hapten complex, allowed to  
25 bind, and then the excess reagent is washed away. A solution  
containing the appropriate substrate is then added to the  
ternary complex of antibody-antigen-antibody. The substrate  
will react with the enzyme linked to the second antibody,  
giving a qualitative visual signal, which may be further  
30 quantitated, usually spectrophotometrically, to give an  
indication of the amount of hapten which was present in the  
sample.

15

Alternately, fluorescent compounds, such as fluorescein and rhodamine, may be chemically coupled to antibodies without altering their binding capacity. When activated by illumination with light of a particular wavelength, the fluorochrome-labeled antibody absorbs the light energy, inducing a state of excitability in the molecule, followed by emission of the light at a characteristic longer wavelength. The emission appears as a characteristic color visually detectable with a light microscope. As in the EIA, the fluorescent labeled antibody is allowed to bind to the first antibody-hapten complex. After washing off the unbound reagent, the remaining ternary complex is then exposed to light of the appropriate wavelength, the fluorescence observed indicates the presence of the hapten of interest. Immunofluorescence and EIA techniques are both very well established in the art and are particularly preferred for the present method. However, other reporter molecules, such as radioisotope, chemiluminescent or bioluminescent molecules, may also be employed. It will be readily apparent to the skilled technician how to vary the procedure to suit the required purpose.

In a further embodiment, the present invention also relates to a kit for the detection of ovarian cancer, the kit being compartmentalized to receive a first container containing an antibody having specificity for the 40 kilodalton subunit and a second container containing a second antibody having specificity for the 40 kilodalton subunit of CA125, or for CA125 itself, one of the antibodies being labeled with a reporter molecule capable of giving a detectable signal and another of the antibodies being immobilized on a solid surface.

1           The present methods and kit are applicable to the  
detection and monitoring of virtually any type of ovarian  
cancer. It is particularly well adapted to the detection by  
cystadenocarcinomas, which comprise about 75% of all ovarian  
5           cancers. <sup>B</sup>

          The practice of the present invention will be more  
fully understood by reference to the following examples.

10

15

20

25

17

30

35



EXAMPLE 1

ISOLATION AND PURIFICATION OF CA125 TUMOR SUBUNIT

CA125 tumor antigen is purified from ascites fluid collected from ovarian tumor patients. Ascites fluid is centrifuged at 10,000 x g prior to storage at -20°C in aliquots of 10 ml. Aliquots (10 ml) are removed for CA125 purification and applied to a 100 cm x 5 cm column filled to half its volume with HW 55 fractogel (EM reagents) and the other half filled with HW 65 fractogel. HW55 and HW65 are molecular filtration beads designed to separate molecules of high molecular weight. The combination of HW55 and HW65 first separates molecules of 700,000 daltons or higher by exclusion from HW55. These molecules are further size fractionated on HW65 which segregates molecules up to  $5 \times 10^6$  daltons. Ascites fluid is processed over this column using 0.15 M NaCl in 20 mM Bis-Tris propane buffer pH 7.2 and 0.1% sodium azide. Nine milliliter fractions are collected, and CA125 activity is monitored using the available commercial assay kit. CA125 elutes over a broad range of molecular size from approximately  $1 \times 10^6$  daltons to  $4 \times 10^6$  daltons. Fractions containing activity are pooled and dehydrated in dialysis bags using flake polyethylene glycol (Bio-rad Aqueside II). The dehydrated material containing the CA125 activity is dehydrated in deionized water and extensively dialyzed (x3) against distilled x deionized water. The cloudy suspension is clarified using centrifugation at 15,000 RPM for 20 minutes to pellet the insoluble material. No CA125 activity is lost to the pellet by this procedure. Further purification of CA125 is accomplished by filtration of the supernatant over a 0.22 um sterile filter (Amicon Inc.). The

1 filtrate may then be aliquoted into 1 ml eppinderf/microtubes  
and lyophilized to dryness using a speed vac centrifuge  
lyophilization procedure.

5 Dried samples are resuspended as needed in SDS  
sample buffer (60 mM Tris pH 6.8 5% mercaptoethanol, 3%  
sodium dodecyl sulfate, 10% glycerol) and electrophoreses  
over 12% polyacrylamide gels according to the method of  
Laemmli (Laemmli U.K. Nature 227: 680, 1970). Commassie  
Blue staining of gels after electrophoresis indicates the  
10 presence of the 40 K dalton protein, a 50 K dalton protein  
and a 92 K dalton protein. The peptide bands can be excised  
from the gel using a standard scalpel after identification of  
the band location with Commassie Blue. The 40 KD band is  
then electroluted from the gel using a Biorad electroeluter  
15 in electroelution buffer (25mM Tris Base 192 MM glycine 0.1%  
SDS pH 8.3) for 3 hours at 150 volts. The sample is  
collected approximately 1 ml and dialyzed against 2 M NaCl  
33 4mM Tris pH 7.0 for 3x changes followed by dialysis  
against deionized water overnight. The sample is dried using a speed  
20 vac and stored at -70°C. Confirmation of purity of  
individual subunits including the 40KD subunit is confirmed  
by reelectrophoresis.

Iodination of either purified CA125 antigen or bead  
selected (antibody selected) antigen followed by SDS  
25 polyacrylamide gels confirms the presence of the 40KD subunit  
of the CA125 tumor derived antigen.

30

35

19

CL B

1

EXAMPLE 2

CL 44

POLYCLONAL ANTIBODY PREPARATION

5

P Rabbits are immunized by intradermal injection with 50 ul of Freund's complete adjuvant containing 20 ug/ml of purified CA125 40KD subunit antigen in 10 locations along the back. The rabbits are first shaved on both sides of the back for easy intradermal injection. The antigen-adjuvant mixture is prepared by mixing in two connected 1 ml glass typhlon syringes and administered in 100 ul doses per location. Forty days after injection rabbits are boosted by direct intravenous injection of 10 ug/100 ul PBS of antigen. Seven to ten days later, rabbits are bled via the ear vein and sera tested for presence of anti-CA125 40KD antibodies. Screening and titration of rabbit antisera is accomplished using <sup>125</sup>I labelled 40KD subunit in the presence of goat anti-rabbit coated latex beads.

10

15

20

25

30

35

EXAMPLE 3

MONOCLONAL ANTIBODY PRODUCTION

CL 1 B  
CL 1/2  
a 5 P  
Monoclonal antibodies are prepared in accordance with the techniques developed by Kohler and <sup>Milstein</sup>~~Mulskin~~ (Eur. J. Immunol. 6: 511-519, 1976). Mice are immunized with CA125 40KD subunit intraperitoneally with 10ug of subunit in 100 ul of Freund's complete adjuvant. Two weeks after the initial injection, the mice are boosted with 10 ug of antigen in 100 ul of alum (10mg/ml) by intraperitoneal injection of 10 ug of antigen in phosphate buffered saline (PBS).

10  
15  
20  
25  
B  
Five days after the last injection and after confirmation of the presence of antibody in mouse sera, the mice are sacrificed and their spleens removed. Spleen cells are obtained by gentle disruption of the spleen in a 7 ml Dounce homogenizer in 3.5-4 ml PBS. The cells are then pelleted at 1200 rpm in a PR6 centrifuge for 6 minutes at room temperature. The supernatant is removed into a suction flask, and the cells are resuspended in 15 ml 0.83% NH<sub>4</sub>Cl. This suspension is incubated at room temperature for 5 minutes then underlain with 10 ml fetal calf serum at 37°C. The cells are again pelleted by centrifugation for 8 minutes, at 1200 rpm at room temperature, then the supernatant is withdrawn into a suction flask and cells resuspended in 20 ml PBS.

The following solutions are prepared for use in the subsequent cell fusion:

Hypoxanthine (H), 680 mg/100 ml H<sub>2</sub>O; add 2-4 drops conc. H<sub>2</sub>SO<sub>4</sub>; heat to dissolve

30 B Aminopterin (A), 46.4 mg/100 ml H<sub>2</sub>O; add 2 drops 1.0 N NaOH to dissolve

- <sup>B</sup><sub>1</sub> Thymidine (T), 775 mg/100 ml H<sub>2</sub>O; add 45 mg glycine  
<sup>B PEG-DME--melt PEG @ 42°C, then add 1 ml DME (@ 37°C); adjust  
<sup>B pH with 1.0 N NaOH to 7.6  
<sup>B DMEM--to 500 ml DME add 37.5 ml a- <sup>✓</sup> horse serum; 37.5 ml  
<sup>5</sup> FCS, 10.0 ml L-glutamine, and 0.5 ml garamycin  
<sup>B 2X HAT-DME--to 200 ml DME add 25.0 ml a- horse serum,  
<sup>B<sup>33</sup> 25.0 ml FCS, 4.0 ml L-glutamine, 0.2 ml garamycin,  
<sup>B 0.8 ml H, and 0.8 ml A, and 0.8 ml T (2X HT-DME omits A)  
<sup>B Cloning Agar--350 mg unwashed Difco agar in 25 ml H<sub>2</sub>O,  
<sup>10</sup> autoclaved  
<sup>B Cloning Medium--to 25 ml 2X DME, add 35 ml filtered,  
<sup>B condition DMEM, 7 ml a- HS, 7 ml FCS, 1 ml L-glutamine,  
<sup>B 0.1 ml garamycin  
<sup>P</sup> Two 30 ml flasks of Sp2/0 cells are added to  
<sup>15</sup> centrifuge tubes and spun down at 1200 rpm for 8 minutes at  
room temperature. The spleen cells are resuspended in 20 ml  
PBS. From each suspension, .01 ml is removed and added to  
0.1 ml 0.4% trypan blue and 0.3 ml PBS and the cells counted.  
<sup>B</sup> The volume of each suspension is adjusted so as to obtain a  
<sup>20</sup> spleen cell to Sp2/0 cell ratio of 10:1, and the suspensions  
are then mixed. The mixture is pelleted at 1200 rpm for 8  
minutes at room temperature and all but about 0.1 ml of  
supernatant removed. The cells are then resuspended in the  
remaining liquid and then added to 1.3 ml of a 1:1 PEG-DME  
<sup>25</sup> solution, pH 7.6. Every minute the volume of the solution is  
doubled with DME until the final volume is 25 ml.  
The cells are again pelleted, the supernatant  
decanted, and the cells resuspended in enough 50% 2X  
HAT-DME/50% conditioned DMEM (the supernatant retained from  
the Sp2/0 cells above) to yield a final concentration of  
<sup>30</sup> about <sup>33</sup>  $3.5 \times 10^6$  spleen cells. The cells are distributed into  
a 96-well flat-bottom microtiter plate (TC-96; Flow  
Laboratories), at 0.1 ml/well. The plate is incubated at</sup></sup></sup></sup></sup></sup></sup></sup></sup></sup>

1 37°C in humidified air/CO<sub>2</sub> until visible colonies appear,  
usually about 10-12 days. The contents of the well is  
transferred to 0.5 ml of HT-DME/conditioned DMEM in a TC-24  
plate (Flow Laboratories). When healthy cell growth appears  
5 (about 2-5 days), about 0.35 ml medium is removed and tested  
for antibody production by enzyme-linked immunosorbent assay  
(ELISA), Hemagglutinin inhibition assay, or neuraminidase  
inhibition assay. When those cells producing the antibodies  
of interest are growing well, one drop from each culture is  
transferred into 1.0 ml DMEM in a TC-24.  
10 To clone the hybrid cells, 25 ml of melted agar and  
76 ml of cloning medium is combined, and 5 ml is pipetted  
into 60 mm petri dishes and left to solidify. Cells from  
DMEM cultures are diluted in 50% DMEM/50% conditioned DMEM,  
15 10<sup>-1</sup> or 10<sup>2</sup> depending on cell growth. Into sterile tubes is  
placed 0.1 ml of each of the two dilutions, and to each is  
added 0.9 ml of cloning medium/agar mixture. This is mixed  
well and poured over the surface of the agar underlay. After  
solidification the plates are incubated at 37°C incubator  
20 until colonies are visible with the naked eye, typically  
about 7-10 days. Colonies are then picked and transferred to  
0.1 ml of DMEM/conditioned DMEM in a TC-99 plate and incubated  
at 37°C in a CO<sub>2</sub> incubator. After the culture is acidic  
(usually 1-4 days), transfer is made to 0.05 ml DMEM in TC-24  
25 plate. When the growth is 50% confluent, the medium is  
removed and tested for antibody production as previously.  
Those clones producing the 40KD subunit specific antibody are  
moved into 5 ml DMEM in 25 cm<sup>2</sup> flasks. Cloned cells are then  
frozen or injected into mice for ascites production.

23

EXAMPLE 4

SANDWICH ASSAY FOR 40KD SUBUNIT ANTIGEN

For detection of the presence of tumor specific antigen in serum, approximately 100 ul of a monoclonal antibody prepared as in Example 3 is immobilized on latex beads and is contacted with about 100 ul of the serum sample to be tested. The antibody and serum are allowed to react for a period of about ten minutes and then rinsed with a solution of PBS. To the latex beads is then added about 100 ul of CA125 specific antibody conjugated to horseradish peroxidase. The labelled antibody bead mixture is incubated for a period of about ten minutes. At this time, an enzyme substrate, hydrogen peroxide and aminoantipyrine, are contacted with the beads, and this mixture is incubated for a period of about 5-10 minutes, at which time the development of color in the sample is an indication of a positive reaction and the presence of the tumor-specific 40KD antigen.

The foregoing procedure is also conducted with two monoclonal antibodies specific for the 40KD antigen, or a monoclonal or a polyclonal, or two polyclonals specific for the 40KD antigen. It is also possible to conduct the assay with only one antibody specific to the 40KD subunit, and a second one which is specific for the CA125 antigen.

CM What is claimed is:

claim  
30

24